Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOAD With Subcutaneous Campath for Adults With Relapsed or Refractory ALL
NCT00262925Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2006
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Primary endpoint: Complete Response Rate. Started Jun 2006; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00262925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262925.